Condition: Prostate Cancer · Sponsor: CHU de Quebec-Universite Laval
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are : 1. Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)? 2. Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB No randomized trial has yet compared LDRB to SBRT head to head.
This description comes directly from the study's public registry record.
Isabelle Thibault, MD, FRCPC · 418-525-4444 · isabelle.thibault.med@ssss.gouv.qc.ca
Eric Vigneault, MD, FRCPC · 418-525-4444 · eric.vigneault.med@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Intégré de Cancérologie, CHU de Québec-Université Laval | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06052683